These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia. Mahévas M; Ebbo M; Audia S; Bonnotte B; Schleinitz N; Durand JM; Chiche L; Khellaf M; Bierling P; Roudot-Thoraval F; Godeau B; Michel M Am J Hematol; 2013 Oct; 88(10):858-61. PubMed ID: 23798363 [TBL] [Abstract][Full Text] [Related]
24. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. Kumar S; Diehn FE; Gertz MA; Tefferi A Ann Hematol; 2002 Jun; 81(6):312-9. PubMed ID: 12107560 [TBL] [Abstract][Full Text] [Related]
25. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Zaja F; Vianelli N; Volpetti S; Battista ML; Defina M; Palmieri S; Bocchia M; Medeot M; De Luca S; Ferrara F; Isola M; Baccarani M; Fanin R Eur J Haematol; 2010 Oct; 85(4):329-34. PubMed ID: 20546023 [TBL] [Abstract][Full Text] [Related]
26. Current management of adult idiopathic thrombocytopenic purpura in practice: a cohort study of 201 patients from a single center. Zimmer J; Andrès E; Noel E; Koumarianou A; Blicklé JF; Maloisel F Clin Lab Haematol; 2004 Apr; 26(2):137-42. PubMed ID: 15053808 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Vianelli N; Galli M; de Vivo A; Intermesoli T; Giannini B; Mazzucconi MG; Barbui T; Tura S; Baccaranion M; Haematologica; 2005 Jan; 90(1):72-7. PubMed ID: 15642672 [TBL] [Abstract][Full Text] [Related]
29. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Reynaud Q; Durieu I; Dutertre M; Ledochowski S; Durupt S; Michallet AS; Vital-Durand D; Lega JC Autoimmun Rev; 2015 Apr; 14(4):304-13. PubMed ID: 25497766 [TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP). Gómez-Almaguer D Hematology; 2012 Apr; 17 Suppl 1():S25-7. PubMed ID: 22507772 [TBL] [Abstract][Full Text] [Related]
32. Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura. Clausen MR; Segel E; Brandsborg M; d'Amore F Eur J Haematol; 2011 Mar; 86(3):256-9. PubMed ID: 21166717 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Vancine-Califani SM; De Paula EV; Ozelo MC; Orsi FL; Fabri DR; Annichino-Bizzacchi JM Platelets; 2008 Nov; 19(7):489-95. PubMed ID: 18979360 [TBL] [Abstract][Full Text] [Related]
34. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat. Rodeghiero F Eur J Haematol Suppl; 2008 Feb; (69):19-26. PubMed ID: 18211569 [TBL] [Abstract][Full Text] [Related]
35. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP). Alasfoor K; Alrasheed M; Alsayegh F; Mousa SA Ann Hematol; 2009 Mar; 88(3):239-43. PubMed ID: 18704420 [TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147 [TBL] [Abstract][Full Text] [Related]
37. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Godeau B; Porcher R; Fain O; Lefrère F; Fenaux P; Cheze S; Vekhoff A; Chauveheid MP; Stirnemann J; Galicier L; Bourgeois E; Haiat S; Varet B; Leporrier M; Papo T; Khellaf M; Michel M; Bierling P Blood; 2008 Aug; 112(4):999-1004. PubMed ID: 18463354 [TBL] [Abstract][Full Text] [Related]
38. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia]. Zhu YC; Wang W; Zhou YH; Wang XM; Wang X; Wang YL; Sun GZ; Hou M Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey. Brah S; Chiche L; Fanciullino R; Bornet C; Mancini J; Schleinitz N; Jean R; Kaplanski G; Harlé JR; Durand JM Ann Hematol; 2012 Feb; 91(2):279-85. PubMed ID: 21710166 [TBL] [Abstract][Full Text] [Related]
40. Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. D'Arena G; Capalbo S; Laurenti L; Del Poeta G; Nunziata G; Deaglio S; Spinosa G; Tarnani M; De Padua L; Califano C; Ferrara F; Cascavilla N Eur J Haematol; 2010 Dec; 85(6):502-7. PubMed ID: 20846302 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]